title: [Comparative assessment of efficacy of local thrombolysis with various fibrinolytics].
abstract: To avoid the characteristic for thrombolytic therapy of pulmonary embolism problems associated with low efficacy and elevated danger haemorrhagic complications may, in our opinion, be possible by means of the method of local thrombolysis worked out in our Clinic (RF Patent No 2376042). The present work was aimed at assessing efficacy of local thrombolysis in patients diagnosed as having pulmonary artery embolism with the drugs urokinase and actilyse. We examined a total of twenty patients. Ten Group One patients underwent local thrombolysis with Urokinase, and the remaining ten Group Two patients were treated with actilyse. We studied the parameters of central and pulmonary haemodynamics. Local thrombolysis with urokinase and actilyse in patients with pulmonary artery embolism turned out to equally efficiently reestablish blood flow in the pulmonary artery, which was confirmed by normalization of central haemodynamics maximally 2 hours after carrying out thrombolytic therapy with urokinase, with acktilyse accelerating this process to take 1 hour only. The proposed method makes it possible to decrease the dose of fibrinolytic agents twofold as compared with the recommended guidelines of the Pharmacopoeia, without losing their efficacy and ensures prevention of haemorrhagic complications.
authors.forename: M I
authors.initials: MI
authors.lastname: Neĭmark
authors.forename: A V
authors.initials: AV
authors.lastname: Akatov
mesh_terms: D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D013923:Thromboembolism / Q000188:drug therapy*; D015912:Thrombolytic Therapy / Q000379:methods*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D016896:Treatment Outcome; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator